Pepper Bio

Pepper Bio aims to end the era of untreatable diseases.

Patients often need luck for effective treatment due to limited and specific medical diagnoses; my personal experience with Alzheimer’s exemplifies the lack of available treatments.

Pepper’s team combines scientific rigor and business acumen, with leaders from prestigious institutions and extensive industry experience.

The drug discovery industry faces issues such as static studies, biased research, and correlation issues that fail to address causation.

Pepper’s transomics approach provides a comprehensive and functional understanding of biology, revealing causal relationships.

Pepper's technology exceeds current target ID approaches, addressing key questions in drug development, and integrates seamlessly into existing pharma processes to optimize target and drug selection.

Pepper’s platform can be applied to large therapeutic areas—oncology, neurodegenerative, and inflammatory diseases—offering significant market opportunities.

Pepper can develop drugs internally for high control and value capture or form partnerships with pharma for early and recurring revenue.

Focusing on oncology, specifically three cancers, Pepper projects to reach clinical trials soon, with significant market potential in the US and EU.

Pepper has established partnerships generating early revenue and is on a trajectory to significantly increase deal sizes, evidenced by strong traction with leading drug developers.

Pepper is leading the shift towards transomics, defining the future of precision medicine and aiming to transform drug discovery by integrating biological understanding.

Join Pepper Bio in driving the future of drug discovery and ending untreatable diseases.